IRIS UniCatt

Lopetuso, Loris Riccardo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.664
AS - Asia 4.665
EU - Europa 3.914
SA - Sud America 946
AF - Africa 122
Continente sconosciuto - Info sul continente non disponibili 11
OC - Oceania 5
Totale 15.327
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.447
SG - Singapore 2.213
CN - Cina 1.060
IT - Italia 816
BR - Brasile 772
SE - Svezia 768
DE - Germania 733
FR - Francia 445
VN - Vietnam 418
IE - Irlanda 216
GB - Regno Unito 210
IN - India 159
FI - Finlandia 154
ID - Indonesia 141
UA - Ucraina 136
JP - Giappone 133
PL - Polonia 122
HK - Hong Kong 115
CA - Canada 103
RU - Federazione Russa 87
MX - Messico 76
TR - Turchia 74
AR - Argentina 70
BD - Bangladesh 59
KR - Corea 47
ZA - Sudafrica 45
NL - Olanda 41
IQ - Iraq 40
BE - Belgio 33
ES - Italia 29
EC - Ecuador 28
IR - Iran 28
SA - Arabia Saudita 21
PK - Pakistan 20
CO - Colombia 19
UZ - Uzbekistan 18
EG - Egitto 16
CL - Cile 15
AT - Austria 14
VE - Venezuela 14
AZ - Azerbaigian 13
AE - Emirati Arabi Uniti 12
CZ - Repubblica Ceca 12
JM - Giamaica 12
KE - Kenya 11
RO - Romania 11
CI - Costa d'Avorio 10
EU - Europa 10
JO - Giordania 10
MA - Marocco 10
NP - Nepal 10
PE - Perù 10
PH - Filippine 10
LT - Lituania 9
TN - Tunisia 9
PY - Paraguay 8
BG - Bulgaria 7
CH - Svizzera 7
OM - Oman 7
RS - Serbia 7
AL - Albania 6
DZ - Algeria 6
GR - Grecia 6
IL - Israele 6
MY - Malesia 6
TH - Thailandia 6
TW - Taiwan 6
BH - Bahrain 5
HU - Ungheria 5
LV - Lettonia 5
AU - Australia 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
HN - Honduras 4
NO - Norvegia 4
UY - Uruguay 4
BA - Bosnia-Erzegovina 3
BO - Bolivia 3
CR - Costa Rica 3
EE - Estonia 3
HR - Croazia 3
KG - Kirghizistan 3
KW - Kuwait 3
LA - Repubblica Popolare Democratica del Laos 3
MD - Moldavia 3
PS - Palestinian Territory 3
PT - Portogallo 3
SI - Slovenia 3
TT - Trinidad e Tobago 3
AM - Armenia 2
AO - Angola 2
BB - Barbados 2
BY - Bielorussia 2
GY - Guiana 2
KH - Cambogia 2
KZ - Kazakistan 2
LB - Libano 2
LY - Libia 2
MK - Macedonia 2
Totale 15.294
Salva come PNG Salva come JPEG
Città #
Singapore 1.262
Chandler 817
Ashburn 566
San Jose 528
Beijing 289
Dublin 206
New York 185
Los Angeles 168
Ho Chi Minh City 141
Lauterbourg 127
Jakarta 124
Rome 123
Tokyo 120
Cattolica 114
Hanoi 112
Boston 105
Hong Kong 97
The Dalles 95
Ann Arbor 93
Warsaw 91
San Mateo 90
Milan 89
Hefei 88
Munich 86
Frankfurt am Main 85
Jacksonville 84
Wilmington 83
Dallas 80
São Paulo 76
Council Bluffs 75
Princeton 73
Fairfield 71
Nanjing 70
Helsinki 69
Houston 66
Marseille 61
Woodbridge 53
Moscow 52
Seattle 52
Dearborn 50
Hangzhou 47
Santa Clara 46
Chicago 42
London 42
Redwood City 42
Izmir 39
Nuremberg 35
Seoul 35
Shanghai 33
North Bergen 32
Stockholm 32
Montreal 31
Brussels 30
Buffalo 30
Chennai 30
Guangzhou 30
Lawrence 28
Orem 28
St Louis 28
Turku 28
Boardman 27
Bremen 27
Johannesburg 27
Lappeenranta 27
Augusta 25
Brooklyn 24
Da Nang 24
Denver 24
Paris 24
Atlanta 23
Shenyang 23
Tianjin 23
Kent 22
Pune 22
Rio de Janeiro 22
Lancaster 21
Nürnberg 21
Phoenix 21
Poplar 21
Redmond 21
Toronto 20
Andover 19
Haiphong 19
Mexico City 19
Nanchang 19
San Francisco 19
Amsterdam 18
Belo Horizonte 18
Baghdad 17
Cambridge 17
Manchester 17
Norwalk 17
Hyderabad 16
Jiaxing 16
Kraków 16
Hebei 15
Curitiba 14
Guayaquil 14
Zhengzhou 14
Düsseldorf 13
Totale 8.310
Salva come PNG Salva come JPEG
Nome #
Food Components and Dietary Habits: Keys for a Healthy Gut Microbiota Composition. 341
International consensus conference on stool banking for faecal microbiota transplantation in clinical practice 267
Gut Microbiota Modulation and Mucosal Immunity: Focus on Rifaximin 230
Nutrition and IBD: Malnutrition and/or Sarcopenia? A Practical Guide 230
Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease 213
Role and mechanisms of action of Escherichia coli nissle 1917 in the maintenance of remission in ulcerative colitis patients: an update 208
The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease 207
Anti-TNF-α-induced psoriasiform lesions in IBD: an abnormal immune activation or a 'patchy cutaneous' immune suppression? 204
The gut barrier: new acquisitions and therapeutic approaches 197
Gut Microbiota in Health, Diverticular Disease, Irritable Bowel Syndrome, and Inflammatory Bowel Diseases: Time for Microbial Marker of Gastrointestinal Disorders? 196
Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications 186
13C-octanoic acid breath test to study gastric emptying time 183
Gelatin tannate ameliorates acute colitis in mice by reinforcing mucus layer and modulating gut microbiota composition: Emerging role for 'gut barrier protectors' in IBD? 173
Skeletal muscle-gut axis: Emerging mechanisms of sarcopenia for intestinal and extra intestinal diseases 172
Actinobacteria: A relevant minority for the maintenance of gut homeostasis 163
Dysbiosis, gut microbiota modulation and intestinal permeability in recurrent cystitis patients and concomitant gastrointestinal pathologies 163
The therapeutic management of gut barrier leaking: the emerging role for mucosal barrier protectors 157
The gastrointestinal microbiome - functional interference between stomach and intestine 155
Dietary Magnesium Alleviates Experimental Murine Colitis Through Upregulation of the Transient Receptor Potential Melastatin 6 Channel 155
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 155
Development and validation of predictive assessment of complicated diverticulitis score 154
Solute Transporter OCTN1/Slc22a4 Affects Disease Severity and Response to Infliximab in Experimental Colitis: Role of Gut Microbiota and Immune Modulation 152
The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin 152
Locally injected Infliximab ameliorates murine DSS colitis: differences in serum and intestinal levels of drug between healthy and colitic mice 151
Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab 148
Intestinal Permeability and Dysbiosis in Female Patients with Recurrent Cystitis: A Pilot Study 146
Nodular lymphoid hyperplasia: A marker of low-grade inflammation in irritable bowel syndrome? 140
Gut microbial flora, prebiotics and probiotics in IBD: their current usage and utility 139
Role of yeasts in healthy and impaired gut microbiota: the gut mycome 139
Bacillus clausii and gut homeostasis: state of the art and future perspectives 139
The use of probiotics in different phases of diverticular disease 139
Microbes and Alzheimer' disease: Lessons from H. Pylori and GUT microbiota 138
Digital integration between hospitals and local health authorities for enhanced vaccination coverage among frail patients: the CareVax study protocol 137
Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review 135
Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients 135
Gut microbiota profiling and gut-brain crosstalk in children affected by pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections 133
Pre- and posttherapy assessment of intestinal soluble mediators in IBD: where we stand and future perspectives 132
Gastrointestinal symptoms and digestive comorbidities in an Italian cohort of patients with COVID-19 131
Pre- and posttherapy assessment of intestinal soluble mediators in IBD: where we stand and future perspectives 129
Specific 13C functional pathways as diagnostic targets in gastroenterology breath-tests: tricks for a correct interpretation 129
Akkermansia muciniphila: key player in metabolic and gastrointestinal disorders 127
Liver Injury, Endotoxemia, and Their Relationship to Intestinal Microbiota Composition in Alcohol-Preferring Rats 126
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 126
Commensal Clostridia: leading players in the maintenance of gut homeostasis 125
Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility 125
Microparticles produced by activated platelets carry a potent and functionally active angiogenic signal in subjects with crohn’s disease 125
Assessment of small intestinal bacterial overgrowth and methane production in patients on chronic proton-pump inhibitor treatment: prevalence and role of rifaximin in its management in primary care 123
Gut Microbiota Modulation in IBD: From the Old Paradigm to Revolutionary Tools 122
Direct effect of infliximab on intestinal mucosa sustains mucosal healing: Exploring new mechanisms of action 122
Characterization of Sarcopenia in an IBD Population Attending an Italian Gastroenterology Tertiary Center 121
Knowledge of Diagnostic and Therapeutic Aspects of IBD Among Nurses Working in Digestive Endoscopy: A Nationwide Italian Survey 121
Gut Microbiota: A Key Modulator of Intestinal Healing in Inflammatory Bowel Disease 119
A modern multidisciplinary approach to the treatment of enterocutaneous fistulas in Crohn’s disease patients 119
Serial Fecal Microbiota Infusions via Colonoscopy for Active Ulcerative Colitis: A Feasibility, Safety, and Translational Monocentric Italian Study 118
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. 118
Can we predict the efficacy of anti-TNF-α agents? 117
Microbiota Composition in Diverticular Disease: Implications for Therapy 116
Gut Microbiota Signatures Are Associated With Psychopathological Profiles in Patients With Ulcerative Colitis: Results From an Italian Tertiary IBD Center 116
Gut microbiota and inflammatory bowel disease: an update 116
Considering gut microbiota disturbance in the management of Helicobacter pylori infection 116
A transition clinic model for inflammatory bowel disease between two tertiary care centers: outcomes and predictive factors 116
Epidemiology of inflammatory bowel disease in the Republic of San Marino: The “EPIMICI – San Marino” study 113
Endoscopic Management of Strictures in Crohn’s Disease: An Unsolved Case 112
Radiomics could predict surgery at 10 years in Crohn's disease 111
Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma 111
Cellular and Molecular Determinants of Biologic Drugs Resistance and Therapeutic Failure in Inflammatory Bowel Disease 110
Increased Faecalibacterium abundance is associated with clinical improvement in patients receiving rifaximin treatment 108
How to face the advent of sars-cov-2 vaccination in ibd patients: Another task for gastroenterologists 107
Intestinal permeability in physiological and pathological conditions: major determinants and assessment modalities 106
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period 106
Secretome modulation of Caco-2 cell line induced by a multi-strain probiotic 105
Bile Acid-Related Regulation of Mucosal Inflammation and Intestinal Motility: From Pathogenesis to Therapeutic Application in IBD and Microscopic Colitis 104
Changes in the intestinal microbiota in patients with a major depressive episode and ulcerative colitis 104
Exploring Bacteroidetes: Metabolic key points and immunological tricks of our gut commensals 104
Impact of the Trophic Effects of the Secretome from a Multistrain Probiotic Preparation on the Intestinal Epithelia 103
Bacillus clausii for the treatment of acute diarrhea in children: A systematic review and meta-analysis of randomized controlled trials 102
Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase 102
Infliximab does not increase colonic cancer risk associated to murine chronic colitis 101
Esophageal microbiome signature in patients with Barrett’s esophagus and esophageal adenocarcinoma 100
Microbiota Composition in Diverticular Disease: Implications for Therapy 97
Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase 97
Human herpesvirus 8-associated colonic Kaposi's sarcoma during vedolizumab treatment in ulcerative colitis: A case report and review of the literature 96
The “dica” endoscopic classification for diverticular disease of the colon shows a significant interobserver agreement among community endoscopists 96
MOREOVER: multiomics MR-guided radiotherapy optimization in locally advanced rectal cancer 96
Coeliac disease under a microscope: Histological diagnostic features and confounding factors 95
Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection—single versus multiple infusions 95
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 94
Gut Virome and Inflammatory Bowel Disease 93
Assessment of Crohn's Disease Activity: Magnetic Resonance Enterography in Comparison with Clinical and Endoscopic Evaluations 91
Relationship between oral microbiota and periodontal disease: a systematic review 90
Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-α on the liver 90
Fecal microbiota transplantation for the treatment of patients with ulcerative colitis and other gastrointestinal conditions beyond Clostridium difficile infection: An update 90
Prevalence of cervical HPV and attitude towards cervical screening in IBD patients under immunomodulatory treatment: A multidisciplinary management experience 90
[Ulcerative colitis] 89
Anti-TNF-α-induced psoriasiform lesions in IBD: An abnormal immune activation or a 'patchy cutaneous' immune suppression? 89
Bariatric procedures and microbiota: patient selection and outcome prediction 89
Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases 88
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 88
Vascular complications in hospitalized patients with inflammatory bowel disease and acute gastroenteritis and colitis: A propensity score-matched study 85
Anti-tumor necrosis factor α therapy associates to type 17 helper T lymphocytes immunological shift and significant microbial changes in dextran sodium sulphate colitis 85
Totale 13.119
Salva come PNG Salva come JPEG
Categoria #
all - tutte 65.640
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.640
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021193 0 0 0 0 0 0 0 0 0 37 128 28
2021/2022949 93 35 23 66 70 25 12 135 48 94 180 168
2022/20232.198 311 305 164 346 135 248 103 176 239 35 75 61
2023/20241.220 76 313 54 74 42 171 79 49 54 43 123 142
2024/20252.476 59 74 206 61 179 84 118 103 328 292 518 454
2025/20266.353 985 194 388 864 1.232 364 1.093 345 501 387 0 0
Totale 15.576